The Comprehensive Analysis of Efficacy and Safety of CalliSpheres^® Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: A Multiple-Center,Cohort Study

This study aimed to investigate the efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization (DEB-TACE) in treating Chinese patients with liver cancer. A total of 367 liver cancer patients from 24 medical centers were consecutively enrolled in this multiple-center, prospective cohort study, including 275 hepatocellular carcinoma (HCC) cases, 37 intrahepatic cholangiocarcinoma (ICC) cases, and 55 secondary liver cancer cases. All the patients received CalliSpheres^® DEB-TACE treatment. Treatment response, overall survival (OS), change of liver function, and adverse events (AEs) were assessed. DEB-TACE treatment achieved 19.9% complete response (CR) and 79.6% objective response rate (ORR), with mean OS of 384 days [95% confidence interval (CI): 375–393 days]. CR and ORR were both higher in HCC patients compared with primary ICC patients and secondary liver cancer patients, while no difference was discovered in OS. Portal vein invasion was an independent risk factor for CR, while portal vein invasion, previous conventional TACE (cTACE) treatment, and abnormal blood creatinine (BCr) were independent risk factors for ORR. In addition, largest nodule size 5.0 cm, abnormal albumin (ALB), and abnormal total bilirubin (TBIL) independently correlated with unfavorable OS. Most liver function indexes were recovered to baseline levels at 1–3 months after DEB-TACE. Common AEs were pain, fever, vomiting, and nausea; most of them were at mild grade. CalliSpheres^® DEB-TACE is efficient and well tolerated in Chinese liver cancer patients. Portal vein invasion, previous cTACE treatment, largest nodule size, abnormal BCr, ALB, and TBIL correlate with worse prognosis independently.     

健脾温肾软坚解毒方、康艾注射液联合低剂量化疗治疗老年脾肾两虚型晚期非小细胞肺癌的临床研究

目的观察健脾温肾软坚解毒方、康艾注射液联合低剂量化疗对老年脾肾两虚型晚期非小细胞肺癌患者瘤灶、免疫功能及无进展生存期的影响。方法将80例老年脾肾两虚型晚期非小细胞肺癌患者随机分为治疗组和对照组,每组40例。对照组予常规剂量化疗,治疗组予健脾温肾软坚解毒方、康艾注射液联合低剂量化疗。化疗2个周期后,观察两组患者瘤灶、免疫功能的变化情况,随访患者的无进展生存期。结果①试验期间,对照组脱落2例,试验组无脱落,最终完成试验者78例,其中治疗组40例,对照组38例。②两组实体瘤疗效比较,差异无统计学意义(P0.05)。③化疗1个周期与化疗前组内比较,两组血清NK、CD3~+、CD4~+、CD8~+水平差异无统计学意义(P0.05);化疗2个周期与化疗前组内比较,治疗组血清CD8~+水平升高(P0.05),对照组血清NK、CD3~+、CD4~+水平降低(P0.05)。化疗1个周期后组间比较,治疗组血清CD3~+、CD4~+水平高于对照组(P0.05);化疗2个周期后组间比较,治疗组血清NK、CD3~+、CD4~+水平高于对照组(P0.05)。④两组患者中位无进展生存时间均为4.5个月,差异无统计学意义(P0.05)。结论健脾温肾软坚解毒方、康艾注射液联合低剂量化疗能有效控制老年肺肾两虚型晚期非小细胞肺癌患者的瘤灶变化,并有利于稳定血清NK、CD3~+和CD4~+水平,保护患者的免疫功能。     

Knockdown of MCM10 Gene Impairs Glioblastoma Cell Proliferation,Migration and Invasion and the Implications for the Regulation of Tumorigenesis

Journal of Molecular Neuroscience - Minichromosome maintenance 10 (MCM10) plays an important role in DNA replication and is expressed in a variety of tumors, including glioma. However, its role and...     

王玉林运用穴位注射治疗肾病综合征并下肢深静脉血栓经验

国家级名老中医王玉林教授以经络学说为指导,运用穴位注射疗法治疗肾病综合征合并下肢深静脉血栓形成,临床疗效显著,该文对王老临床经验进行总结。     

序贯HFNC对中老年患者全麻胆囊切除术后低氧血症与再插管率的影响

目的探讨拔除气管插管后序贯经鼻高流量氧疗（HFNC）对中老年患者全麻胆囊切除术后低氧血症和再插管率的影响。 方法采用前瞻性随机对照研究，选取2019年1月至12月新疆维吾尔自治区第三人民医院重症医学科收治的全麻下行胆囊切除术患者90例，将其随机分为HFNC组（30例）、鼻导管组（30例）、面罩组（30例）。比较拔除气管插管前后各组间心率（HR）、血压和血气分析指标［动脉血氧分压（PaO₂）、动脉血二氧化碳分压（PaCO₂）、氧合指数］，以及拔管后患者不适感和再插管率情况。 结果拔除气管插管前，3组患者间HR、收缩压（SBP）、PaO₂、PaCO₂、氧合指数比较，差异无统计学意义（P＞0.05）。拔管后1 h，3组患者间HR和SBP比较，差异无统计学意义（P＞0.05）；HFNC组患者的PaO₂与氧合指数均高于面罩组，PaCO₂低于面罩组，差异均有统计学意义（P=0.013，P=0.009，P=0.031），但与鼻导管组比较，差异均无统计学意义（P=0.106，P=0.101，P=0.545）；面罩组与鼻导管组相比，PaO₂和氧合指数差异均无统计学意义（P=0.363，P=0.314）。鼻导管组黏膜干燥抱怨所占比例最高，面罩组的幽闭恐惧和恶心呕吐所占比例最高，差异均有统计学意义（P＜0.05）。3组患者再插管率比较，差异无统计学意义（P=0.484）。 结论对于中老年全麻下行胆囊切除术后低氧血症的患者而言，相比面罩氧疗，拔除气管插管后采用序贯HFNC可以更好地改善患者的PaO₂、PaCO₂、氧合指数和不适感，但不能降低再插管率。     

逍遥散对肝郁脾虚证模型大鼠海马TPH2与IDO1的调节作用

目的:观察肝郁脾虚证模型大鼠海马色氨酸羟化酶2(TPH2)与吲哚胺-2,3-双加氧酶1(IDO1)表达的变化并探讨逍遥散的调节作用。方法:雄性SD大鼠随机分成4组,分别是正常组、模型组、逍遥散组、氟西汀组,每组6只。采用慢性束缚应激的方法制备大鼠肝郁脾虚证模型,造模持续21 d。通过荧光定量PCR与Western-blot方法检测各组大鼠海马TPH2与IDO1的表达情况。结果:模型组大鼠海马TPH2 mRNA的表达水平低于其余3组大鼠(P0.05),逍遥散与氟西汀对TPH2 mRNA的表达有一定的上调作用;模型组大鼠海马IDO1 mRNA的表达显著增加(P0.01),逍遥散与氟西汀对IDO1 mRNA表达的下调作用明显(P0.01),且逍遥散对IDO1 mRNA的下调作用更明显。模型组、逍遥散组、氟西汀组大鼠海马TPH2的蛋白的表达低于正常组(P0.01),逍遥散组TPH2蛋白表达高于模型组(P0.05);模型组大鼠海马IDO1的蛋白表达显著高于其余3组(P0.01)。结论:肝郁脾虚证模型大鼠海马TPH2的表达减少,IDO1的表达增多,逍遥散可能通过调节海马TPH2与IDO1的表达水平进而影响5-HT的含量,起到治疗作用。     

小檗碱对大肠杆菌基因转录抑制作用的实验研究

目的：对小劈碱（BBR）对大肠杆菌的抑制作用的分子靶点进行探讨。方法：鉴于BBR对DNA结合的偏好性,本文从基因转录表达水平对BBR的大肠杆菌生长抑制作用靶点进行实验研究。结果：BBR对于大肠杆菌基因上游调控元件UP element具有较强的亲和力,而在此元件地转录起始区含有TATA碱基序列。进一步对启动子上游含有UP element调控元件的基因sulA、recA、16S和启动子上游不含UP element调控元件的基因lpxC、secG、mutT的mRNA表达比较表明,BBR抑制sulA、recA、16S的表达,对lpxC、secG、mutT无明显作用,提示TATA序列是BBR的作用靶点。结论：本结果对从基因转录水平探讨BBR抑菌作用提供了新思路。